This publication carries latest news on appointments and hires in and around the North America wealth management sector.

EXTHERA Capital, a New York-based hedge fund manager concentrating in global therapeutics, has appointed Rael Mazansky as director of research, working alongside the firm’s co-founder and chief investment officer, Ori Hershkovitz.

“We are excited to hire an individual with a long and impressive history in healthcare investing. Rael will strengthen our team as we continue to develop the best human capital to produce innovative research and guidance for the portfolio,” Daniel Malek, co-founder and chief executive, said.

Mazansky joins NEXTHERA after being a healthcare portfolio manager at Surveyor Capital (Citadel), and previously holding senior biotech analyst roles at Perceptive Advisors and Ridgeback Capital.
NEXTHERA Capital, with more than $250 million in assets under management, is a fundamental long/short equity hedge fund manager concentrating in global therapeutics (large cap pharmaceuticals, specialty pharmaceuticals/generics, and biotech). Ori Hershkovitz was formerly head of pharmaceutical research at Sphera Funds Management, and Malek was previously allocating capital to external managers at EJS Investment.